U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H10I4NO4.Na
Molecular Weight 798.8518
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXTROTHYROXINE SODIUM ANHYDROUS

SMILES

[Na+].N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C([O-])=O

InChI

InChIKey=YDTFRJLNMPSCFM-UTONKHPSSA-M
InChI=1S/C15H11I4NO4.Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;/h1-2,4-5,12,21H,3,20H2,(H,22,23);/q;+1/p-1/t12-;/m1./s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C15H10I4NO4
Molecular Weight 775.8621
Charge -1
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Dextrothyroxine is the dextrorotary isomer of the synthetic thyroxine. It is an antihyperlipidemic agent. The mechanism of action is not completely understood, but dextrothyroxine apparently acts in the liver to stimulate formation of low-density lipoprotein (LDL) and, to a much greater extent, to increase catabolism of LDL. This leads to increased excretion of cholesterol and bile acids via the biliary route into the feces, with a resulting reduction in serum cholesterol and LDL. Dextrothyroxine has no significant effect on high-density lipoproteins (HDL). Inherently, it will also bind to thyroid receptors and as it is a prohormone, it will bind as a substrate to iodide peroxidase.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CHOLOXIN

T1/2

ValueDoseCo-administeredAnalytePopulation
6 day
6 mg 1 times / day unknown, oral
LEVOTHYROXINE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
6 mg 1 times / day unknown, oral
LEVOTHYROXINE plasma
Homo sapiens

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
In Vitro Use Guide
The relative binding affinities of liothyronine (L-T3), levothyroxine (L-T4), D-triiodothyronine (D-T3), and dextrothyroxine (D-T4) were measured in vitro. Solubilized nuclear receptors were prepared from rat anterior pituitaries. L-T3 had the highest binding for the nuclear receptor (taken as 100%). L-T4 and D-T3 binded to the nuclear receptor with similar affinities (11% and 13%, respectively), while the affinity of D-T4 represents only 3% that of L-T3.
Substance Class Chemical
Record UNII
J60FX7V025
Record Status Validated (UNII)
Record Version